{"id":"paclitaxel-dosing-according-to-smpc","safety":{"commonSideEffects":[{"rate":"High (> 40%)","effect":"Neutropenia"},{"rate":"High (> 40%)","effect":"Anemia"},{"rate":"Moderate (10-40%)","effect":"Thrombocytopenia"},{"rate":"Moderate (10-40%)","effect":"Fatigue"},{"rate":"Low (< 10%)","effect":"Mucositis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Paclitaxel binds to tubulin, stabilizing microtubules and preventing their disassembly. This prevents the formation of the mitotic spindle, a structure essential for cell division. As a result, cancer cells are unable to divide and multiply, leading to cell death.","oneSentence":"Paclitaxel works by inhibiting cell division, thereby preventing cancer cells from multiplying.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:25.150Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant treatment of node-positive breast cancer"},{"name":"Adjuvant treatment of completely resected non-small cell lung cancer"},{"name":"Treatment of ovarian cancer"},{"name":"Treatment of pancreatic cancer"},{"name":"Treatment of AIDS-related Kaposi's sarcoma"}]},"trialDetails":[{"nctId":"NCT01326767","phase":"PHASE3","title":"Central European Society for Anticancer Research (CESAR) Study of Paclitaxel Therapeutic Drug Monitoring","status":"COMPLETED","sponsor":"Central European Society for Anticancer Drug Research","startDate":"2011-03","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":366}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Paclitaxel dosing according to SmPC","genericName":"Paclitaxel dosing according to SmPC","companyName":"Central European Society for Anticancer Drug Research","companyId":"central-european-society-for-anticancer-drug-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Paclitaxel works by inhibiting cell division, thereby preventing cancer cells from multiplying. Used for Adjuvant treatment of node-positive breast cancer, Adjuvant treatment of completely resected non-small cell lung cancer, Treatment of ovarian cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}